Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cancers 13.2021, 16, art. 4017, ISSN 2072-6694, doi:10.3390/cancers13164017
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2021
- Urheber
-
Gröner, Daniel
Baumgarten, Justus
Haefele, Sebastian
Happel, Christian
Klimek, Konrad
Mader, Nicolai
Nguyen Ngoc, Christina
Tselis, Nikolaos
Chun, Felix
Grünwald, Frank
Sabet, Amir
- URN
-
urn:nbn:de:hebis:30:3-626437
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:48 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gröner, Daniel
- Baumgarten, Justus
- Haefele, Sebastian
- Happel, Christian
- Klimek, Konrad
- Mader, Nicolai
- Nguyen Ngoc, Christina
- Tselis, Nikolaos
- Chun, Felix
- Grünwald, Frank
- Sabet, Amir
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2021
Ähnliche Objekte (12)
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer
Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy
Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer
Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy
Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Comparison of tumor heterogeneity assessed with textural parameters in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT in patienst with metastatic prostate cancer
Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer
Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy
Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer